Biotechnology company GenScript Biotech Corporation (HK:1548) said on Wednesday that it has entered into a strategic partnership agreement for the manufacturing service of GMP plasmids with Genopis Inc.

Genopis specialises in plasmid DNA-based technology and provides contract development and manufacturing organisation (CDMO) services.

Under the new agreement, the companies will establish a revenue-sharing agreement for the promotion, selling and production of GMP plasmids globally.

"The partnership will not only help customers effectively diversify risks, but also lower costs and shorten the production cycle, and maximise customer resources to better use in the early R&D phase," said Paul Kim, chief strategic officer of Genopis.

Headquartered in San Diego, California, Genopis serves as a site for cGMP manufacturing operations, with current capabilities suited for microbial-based products and expandable for future mammalian-based products.